Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Beijing Tong Ren Tang Chinese Medicine Co Ltd stock forecast from 0 analysts, the average analyst target price for Beijing Tong Ren Tang Chinese Medicine Co Ltd is not available over the next 12 months. Beijing Tong Ren Tang Chinese Medicine Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Beijing Tong Ren Tang Chinese Medicine Co Ltd is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Beijing Tong Ren Tang Chinese Medicine Co Ltd’s stock price was HKD 9.10. Beijing Tong Ren Tang Chinese Medicine Co Ltd’s stock price has changed by +1.45% over the past week, -1.30% over the past month and -42.77% over the last year.
No recent analyst target price found for Beijing Tong Ren Tang Chinese Medicine Co Ltd
No recent average analyst rating found for Beijing Tong Ren Tang Chinese Medicine Co Ltd
Company Overview Beijing Tong Ren Tang Chinese Medicine Co Ltd
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland China, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates retail outlets in Hong Kong and in other countries and regions in Asia, Oceania, North America, and Europe. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wan Chai, Hong Kong. Read Less
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland C...Read More
Frequently Asked Questions About Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613:HK) Stock
Stock Target Advisor's fundamental analysis for Beijing Tong Ren Tang Chinese Medicine Co Ltd's stock is Slightly Bullish .
3613:HK stock's dividend yield is 3.59%.
Our analysis grades 3613:HK stock's dividend yield at F. This means that 3613:HK stock's dividend yield is above 48% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3613:HK may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 3613:HK's stock to indicate what its average analyst target is.
3613:HK stock's Price/Earning ratio is 14.15.
Our analysis grades 3613:HK stock's Price / Earning ratio at F. This means that 3613:HK stock's Price/Earning ratio is above 64% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3613:HK may be a overvalued for its sector.
The last closing price of 3613:HK's stock was HKD 9.10.
The most recent market capitalization for 3613:HK is HKD 7.70B.
Unfortunately we do not have enough analyst data on 3613:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Beijing Tong Ren Tang Chinese Medicine Co Ltd's stock.
As per our most recent records Beijing Tong Ren Tang Chinese Medicine Co Ltd has 798 Employees.
Beijing Tong Ren Tang Chinese Medicine Co Ltd's registered address is Office Tower, Wan Chai, Hong Kong.
You can get more information about it from Beijing Tong Ren Tang Chinese Medicine Co Ltd's website at https://www.tongrentangcm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 3613:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
